Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025PharmaceuticsOpen Access

Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSafaa BazbazHebrew University of JerusalemIZIrina ZaidmanHebrew University of JerusalemEEEhud Even‐OrHebrew University of Jerusalem

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows similar event-free survival in pediatric patients receiving once-daily or four-times-daily busulfan, suggesting dosing flexibility.

Key Points

  • There was no significant difference in 100-day event-free survival between the once-daily and four-times-daily busulfan dosing regimens.
  • The study involved 70 pediatric patients, with comparable rates of acute graft-versus-host disease and sinusoidal obstruction syndrome in both groups.
  • Analysis of liver enzyme levels revealed no significant differences, indicating similar safety profiles for both busulfan regimens.
  • Findings highlight the need for further prospective studies to validate the clinical outcomes of busulfan dosing in pediatric patients.

Cite This Study

Bazbaz et al. (2025) studied this question.

synapsesocial.com/papers/68af5210ad7bf08b1ead9724https://doi.org/10.3390/pharmaceutics17081081
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes2002 · 290 citations
  2. 2Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance2022 · 14 citations
  3. 3Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes2006 · 31 citations
  4. 4Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation2007 · 86 citations